Chimeric Antigen Receptor T-cell Therapy (CAR T)

This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T-cells via a leukapheresis procedure. These cells are sent to a centralized manufacturing facility where they are genetically modified to produce specific chimeric antigen receptors and expanded in a cell culture. This process may take up to few weeks. This product is then returned to the treating facility and re-infused into the patient recovery. (Srivastava & Riddell, 2018). Chimeric antigen receptor T-cell therapy is used to treat certain blood cancers, and still being studied in the treatment of other types of cancer. This is also called as CAR-T Immunotherapy. The first CAR T cell therapy was approved by FDA in 2017, and there are now 6 approved CAR T therapies